Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7697936 | 0.87 | MAPT (0.39) | LMNASMN1; SMN2MAPTALDH1A1KMT2A | |
| SCHEMBL2267030 | 0.81 | ALDH1A1 (0.46) | LMNASMN1; SMN2MAPTALDH1A1KMT2A | |
| SCHEMBL31419067 | 0.81 | ALDH1A1 (0.46) | LMNASMN1; SMN2MAPTALDH1A1KMT2A | |
| SCHEMBL21410907 | 0.78 | PAX8 (0.38) | LMNASMN1; SMN2MAPTALDH1A1KMT2A | |
| SCHEMBL1620480 | 0.77 | KMT2A (0.43) | LMNAMAPTKMT2AMEN1L3MBTL1 | |
| SCHEMBL9438386 | 0.77 | MAPT (0.47) | LMNAMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL2483154 | 0.77 | SMN1; SMN2 (0.46) | IDO1LMNASMN1; SMN2MAPTALDH1A1 | |
| Fluoride SCHEMBL23234546 | 0.76 | NPC1 (0.43) | LMNAMAPTKMT2AMEN1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL28516416 | 0.76 | KMT2A (0.42) | LMNAMAPTKMT2AMEN1L3MBTL1 | |
| SCHEMBL10745616 | 0.75 | KMT2A (0.53) | LMNASMN1; SMN2MAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105001302-A | Cyclic peptide inhibitors of hepatitis C virus replication | INTERMUNE INC | 2015-10-28 | — | — | CN | disclosed |
| CN-102741270-B | Cyclic peptide inhibitors of hepatitis C virus replication | INTERMUNE INC | 2015-07-22 | — | — | CN | disclosed |
| EP-2483290-A1 | CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | Intermune, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2225245-B1 | N-phenyl-imidazo(1,2-a)pyridine-2-carboxamide compounds, preparation thereof and therapeutic application thereof | SANOFI SA (FR) | 2011-10-19 | — | — | EP | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011038293-A1 | CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2011038293-A1 | CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20100317620-A1 | N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-12-16 | — | — | US | disclosed |
| CN-101910175-A | N-phenylimidazo [1,2-a ] pyridine-2-carboxamide compounds, preparation and therapeutic use thereof | SANOFI AVENTIS | 2010-12-08 | — | — | CN | disclosed |
| EP-2225245-A2 | N-PHENYL-IMIDAZOÝ1,2-A¨PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | Sanofi-Aventis (FR) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009115651-A2 | N-PHENYL-IMIDAZO[1,2-A]PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317620-A1 | N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION AND THERAPEUTIC USE THEREOF | GLS, REN, XDH | IDO1 1714/4885LMNA 890/4885SMN1; SMN2 172/4885 |
| US-20110081315-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, EIF4A2 | IDO1 1194/4885LMNA 1625/4885SMN1; SMN2 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.